ImmunityBio Directors Sold $3.92M Before Earnings Miss
Three ImmunityBio board members sold $3.92 million in shares at prices between $7.18 and $9.50 between June 4 and July 2, 2026, weeks before the company reported a -175% Q2 EPS miss, its second consec
ImmunityBio Directors Cashed Out Ahead of Earnings Miss
NEW YORK, August 16 —
ImmunityBio, Inc. (IBRX) has a timing problem: three board members sold $3.92 million in shares at prices as high as $9.50 between June 4 and July 2, 2026, weeks before the company reported a -175% EPS surprise, its second consecutive miss and the worst in four quarters. The stock now sits at $7.57, below every insider exit price except one.
- Q2 EPS miss of -175%: $-0.22 actual versus $-0.08 estimated, per the August 4 8-K
- $281M trailing operating cash outflow against $360M in cash, burn exceeds full-year revenue of ~$170M
- 32.2% of float sold short; directors Cohen and Selecky exited at $9.50 and $9.00, $9.02, now above market
The Selling Pattern Tells Its Own Story
Directors Christobel Selecky, Cheryl Cohen, and Barry J. Simon exercised options at strike prices of $2.84 to $2.99 per share and immediately sold into the open market, a classic exercise-and-sell pattern that converts in-the-money options directly to cash. Selecky cleared roughly $2.31 million across three transactions at $9.00, $9.02; Cohen took $1.25 million at $9.50; Simon generated $362,000 at $7.18 to $7.88. Zero purchases were recorded in the same window. Insider ownership remains 62.2% of shares outstanding, so the founding team retains control, but the three directors who sold chose to convert upside into cash at prices that now stand above the market.
Revenue Growth Masks a Deteriorating Cash Picture
ImmunityBio makes Anktiva (N-803), an FDA-approved immunotherapy for BCG-unresponsive non-muscle invasive bladder cancer, which generated trailing revenue of ~$170 million, up 93.9% year-over-year, at a 99.3% gross margin, the signature economics of an early-stage biologic with negligible cost of goods. The problem sits below the gross line: $281 million in annual operating cash outflow against $360 million in cash means the runway is measured in quarters, not years. Total debt of $1.23 billion amplifies the pressure. Meanwhile, FDA scrutiny reportedly prompted the company to withdraw promotional content and tighten oversight procedures around Anktiva marketing, a complication the 93.9% growth rate does not reflect.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| IBRX | $8.0B | n/a | +211.5% |
| IOVA | $3.2B | n/a | +179.2% |
| SMMT | $10.6B | n/a | -49.2% |
| RXRX | $1.7B | n/a | -42.8% |
| SLS | $2.6B | n/a | +638.7% |
| BBIO | $15.6B | 215.7x | +62.9% |
What Changes the Thesis
The founder is publicly highlighting a new Anktiva-NK cell therapy combination study as an imminent catalyst, and traders have described IBRX as entering a "heavy catalyst phase" amid uncertainty at the FDA. The analyst consensus target of $12.75 against a $7.57 price implies the market is discounting something real. The specific number to watch: quarterly operating cash burn. If the Anktiva commercial ramp begins closing the gap between $170 million in revenue and $281 million in outflow, the bearish read weakens materially. If the next quarter produces a third consecutive EPS miss, the $360 million cash balance becomes the only story. Run the free ImmunityBio, Inc. deep-dive at ImmunityBio, Inc.'s latest numbers before the next catalyst lands.
Current fundamentals, valuation and filing history for ImmunityBio, Inc. (IBRX) are tracked on its Basis Report page.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Did ImmunityBio insiders sell before earnings?
Yes. Three board members, Christobel Selecky, Cheryl Cohen, and Barry J. Simon, sold a combined $3.92 million in shares between June 4 and July 2, 2026. The company then reported a -175% EPS miss on August 4. Zero purchases were recorded in the same window.
What was ImmunityBio's Q2 EPS result?
ImmunityBio reported Q2 EPS of $-0.22 against a consensus estimate of $-0.08, a -175% surprise per the August 4 8-K. It was the second consecutive miss and the worst result in four quarters.
How much cash does ImmunityBio have?
ImmunityBio holds $360 million in cash against $281 million in trailing annual operating cash outflow. That burn rate exceeds the company's full-year revenue of approximately $170 million, putting the runway in quarters rather than years. Total debt stands at $1.23 billion.
What is Anktiva and what does it earn?
Anktiva (N-803) is an FDA-approved immunotherapy for BCG-unresponsive non-muscle invasive bladder cancer. It generated trailing revenue of approximately $170 million, up 93.9% year-over-year, at a 99.3% gross margin. FDA scrutiny reportedly prompted the company to withdraw promotional content and tighten oversight procedures around its marketing.
What is the analyst price target for ImmunityBio?
The analyst consensus target stands at $12.75, against a current price of $7.57. The founder is publicly highlighting a new Anktiva-NK cell therapy combination study as a near-term catalyst, with traders describing the stock as entering a heavy catalyst phase.
Three ImmunityBio directors sold a combined $3.92 million in IBRX shares at prices between $7.18 and $9.50 in June and early July 2026 — weeks before the company reported its worst earnings miss in four quarters. Now the founder is publicly promoting new Anktiva combination studies as catalysts while the stock sits at $7.57, below most insider exit prices.